Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma

Cancer Research

Volumn 60, Issue 10, 2000, Pages 2689-2695

  Wong, Carmen P ^a,b   Levy, Ronald ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHIMERIC PROTEIN; T LYMPHOCYTE RECEPTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY; VACCINE PRODUCTION; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0034658011     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1, 1999.
2. Shipp, M. A., Mauch, P. M., and Harris, N. L. Non-Hodgkins's lymphomas. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, p. 2165. Philadelphia: Lippincott-Raven, 1997.
3. Deisseroth, A. B., Kantarjian, H., Andreeff, M., Talpaz, M., Keating, K. J., Khouri, I., and Champlin, R. B. Chronic leukemias. In: V. T. DeVila, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, p. 2321. Philadelphia: Lippincott-Raven, 1997.
4. Okada, C. Y., Wong, C. P., Denney, D. W., and Levy, R. TCR vaccines for active immunotherapy of T cell malignancies. J. Immunol., 159: 5516-5527, 1997.
5. Wong, C. P., Okada, C. Y., and Levy, R. TCR vaccines against T cell lymphoma: QS-21 and 1L-12 adjuvants induce a protective CD8+ T cell response. J. Immunol., 162: 2251-2258, 1999.
6. Campbell, M. J., Esserman, L., Byars, N. E., Allison, A. C., and Levy, R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol., 145: 1029-1036, 1990.
7. Syrengelas, A. D., and Levy, R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J. Immunol., 162: 4790-4795, 1999.
8. George, A. J., and Stevenson, F. K. Prospects for the treatment of B cell tumors using idiotypic vaccination. Int. Rev. Immunol., 4: 271-310, 1989.
9. Yang, Y., Jooss, K. U., Su, Q., Ertl, H. C., and Wilson, J. M. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther., 3: 137-144, 1996.
10. Yang, Y., Li, Q., Ertl, H. C., and Wilson, J. M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol., 69: 2004-2015, 1995.
11. Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., and Mehtali, M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol., 70: 4805-4810, 1996.
12. He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., and Vogelstein, B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA, 95: 2509-2514, 1998.
13. Allison, J. P., McIntyre, B. W., and Bloch, D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J. Immunol., 129: 2293-2300, 1982.
14. Lin, A. L., Devaux, B., Green, A., Sagerstrom, C., Elliot, J. F., and Davis, M. M. Expression of T cell antigen receptor heterodimers in a lipid-linked form. Science (Washington DC), 249: 677-679, 1990.
15. Pelletier, J., and Sonenberg, N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature, 334: 320-325, 1988.
16. Graham, F. L., and Prevec, L. Methods for construction of adenovirus vectors. Mol. Biotechnol., 3: 207-220, 1995.
17. Kensil, C. R., Wu, J. Y., Anderson, C. A., Wheeler, D. A., and Amsden, J. QS-21 and QS-7: purified saponin adjuvants. Dev. Biol. Stand., 92: 41-47, 1998.
18. Campbell, M. J., Carroll, W., Kon, S., Thielemans, K., Rothbard, J. B., Levy, S., and Levy, R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol., 139: 2825-2833, 1987.
19. George, A. J., Folkard, S. G., Hamblin, T. J., and Stevenson, F. K. Idiotypic vaccination as a treatment for a B cell lymphoma. J. Immunol., 141: 2168-2174, 1988.
20. Hsu, F. J., Caspar, C. B., Czerwinski, D., Kwak, L. W., Liles, T. M., Syrengelas, A., Taidi-Laskowski, B., and Levy, R. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood, 89: 3129-3135, 1997.
21. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., and Levy, R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med., 2: 52-58, 1996.
22. Kozarsky, K. F., and Wilson, J. M. Gene therapy: adenovirus vectors. Curr. Opin. Genet. Dev., 3: 499-503, 1993.
23. Wan, Y., Bramson, J., Carter, R., Graham, F., and Gauldie, J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther., 8: 1355-1363, 1997.
24. Warmer, G., Duffour, M. T., Uyttenhove, C., Gajewski, T. F., Lurquin, C., Haddada, H., Perricaudet, M., and Boon, T. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. Int. J. Cancer, 67: 303-310, 1996.
25. Chen, P. W., Wang, M., Bronte, V., Zhai, Y., Rosenberg, S. A., and Restifo, N. P. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol., 156: 224-231, 1996.
26. Juillard, V., Villefroy, P., Godfrin, D., Pavirani, A., Venet, A., and Guillet, J. G. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur. J. Immunol., 25: 3467-3473, 1995.
27. Gahery-Segard, H., Molinier-Frenkel, V., Le Boulaire, C., Saulnier, P., Opolon, P., Lengagne, R., Gautier, E., Le Cesne, A., Zitvogel, L., Venet, A., Schatz, C., Courtney, M., Le Chevalier, T., Tursz, T., Guillet, J. G., and Farace, F. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J. Clin. Invest., 100: 2218-2226, 1997.
28. Rosenberg, S. A., Zhai, Y., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Seipp, C. A., Einhorn, J. H., Roberts, B., and White, D. E. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst., 90: 1894-1900, 1998.
29. Christ, M., Lusky, M., Stoeckel, F., Dreyer, D., Dieterle, A., Michou, A. I., Pavirani, A., and Mehtali, M. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol. Lett., 57: 19-25, 1997.
30. Michou, A. I., Santoro, L., Christ, M., Julliard, V., Pavirani, A., and Mehtali, M. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther., 4: 473-482, 1997.
31. Tao, M. H., and Levy, R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma [see comments]. Nature (Lond.)., 362: 755-758, 1993.
32. King, C. A., Spellerberg, M. B., Zhu, D., Rice, J., Sahota, S. S., Thompsett, A. R., Hamblin, T. J., Radl, J., and Stevenson, F. K. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma [see comments]. Nat. Med., 4: 1281-1286, 1998.
33. Spellerberg, M. B., Zhu, D., Thompsett, A., King, C. A., Hamblin, T. J., and Stevenson, F. K. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J. Immunol., 759: 1885-1892, 1997.
34. Hirschowitz, E. A., Leonard, S., Song, W., Ferris, B., Leopold, P. L., Lewis, J. J., Bowne, W. B., Wang, S., Houghton, A. N., and Crystal, R. G. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther., 5: 975-983, 1998.
35. Bramson, J. L., Hitt, M., Gauldie, J., and Graham, F. L. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther., 4: 1069-1076, 1997.
36. Molnar-Kimber, K. L., Sterman, D. H., Chang, M., Kang, E. H., ElBash, M., Lanuti, M., Elshami, A., Gelfand, K., Wilson, J. M., Kaiser, L. R., and Albelda, S. M. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy Phase I clinical trial for localized mesothelioma. Hum. Gene Ther., 9: 2121-2133, 1998.
37. Mack, C. A., Song, W. R., Carpenter, H., Wickham, T. J., Kovesdi, I., Harvey, B. G., Magovern, C. J., Isom, O. W., Rosengart, T., Falck-Pedersen, E., Hackett, N. R., Crystal, R. G., and Mastrangeli, A. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype Hum. Gene Ther., 8: 99-109, 1997.
38. Brossart, P., Goldrath, A. W., Butz, E. A., Martin, S., and Bevan, M. J. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol., 158: 3270-3276, 1997.
39. Ribas, A., Butterfield, L. H., McBride, W. H., Jilani, S. M., Bui, L. A., Vollmer, C. M., Lau, R., Dissette, V. B., Hu, B., Chen, A. Y., Glaspy, J. A., and Economou, J. S. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res., 57: 2865-2869, 1997.
40. Wan, Y., Emtage, P., Foley, R., Carter, R., and Gauldie, J. Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression. Int. J. Oncol., 14: 771-776, 1999.